Home / Resources / Videos / ADA 2017 / Thomas Seck Part 1, Introduction and Empagliflozin for Diabetes

Thomas Seck Part 1, Introduction and Empagliflozin for Diabetes

In part 1 of this Exclusive Interview, Dr. Thomas Seck talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about the Boehringer Ingelheim relationship with Eli Lilly, Empagliflozin for diabetes, and the cardiovascular effects of certain diabetes medications.

Thomas Seck, MD, is VP of Clinical Development and Medical Affairs at Boehringer Ingelheim.

Transcript of this video segment:

Steve: This is Steve Freed. We are here at American diabetes association, 77th scientific studies and we are here to present to you some exciting interviews with some of the top endos from all over the world. The name is Thomas Seck, MD and tell us little bit about your self

Dr. Seck: Thank you for having me. I am Thomas Seck. I am head of clinical development and medical affairs for the US organization of Boehringer Ingelheim. I am an endocrinologist by training and in the pharmaceutical industry for about a decade.

Steve: Your company obviously has a relationship with Eli Lilly.

Dr. Seck: Yes we do. There is a diabetes alliance between Boehringer Ingelheim and Eli Lilly covering a number of compounds. It started in 2011 and its really a unique and one-of-a-kind relationship to partner in developing and commercialization of various diabetes products.

Steve: it’s been about 3 years when Empagliflozin came out?

Dr. Seck: Yes

Steve: And it kind of caught everybody by surprise because you discovered something that nobody really ever discussed. We always thought that diabetes is all about blood sugars (that’s because we could do something about blood sugars) and now with this drug we can actually do something about helping people live longer and prevent cardiovascular disease. Since most people with diabetes do not die from diabetes but they die from cardiovascular disease, this was a huge breakthrough.

Dr. Seck: Yes

Steve: Your study basically provided the information, so maybe we can talk a little bit about that. What data regarding Jardiance and the outcome is being presented here?

Dr. Seck: Maybe I can take a step back and add to what you already mentioned. I think the importance of cardiovascular disease in diabetes cannot be underestimated. The likelihood of having cardiovascular disease if you have diabetes is 2 to 4 times higher compared to a person without diabetes. On top of that, two out of three patients die due to cardiovascular disease if you have diabetes. So, it’s a very serious problem: it has impact on your life expectancy, so if you are diagnosed with diabetes at age of 60 and at the same time have established cardiovascular disease, your life expectancy is reduced by 12 years compared to individual without these conditions. So it’s a very serious and important condition. When empiric outcomes published in September of 2015, it’s a European diabetes meeting in Stockholm: I think that was first time we saw diabetes medication that showed benefit in cardiovascular outcome. So this is very large, robust study with over 7,000 patients. All of them had type 2 diabetes and cardiovascular disease. What we observed is called 3-point maze, major adverse cardiovascular accident. That endpoint was reduced by 14% but more importantly, this was entirely driven by a reduction of cardiovascular death by 38%. So at that time and still to this day, I think that this kind of results is really considered landmark in management of diabetes. And really opens up for physicians and patients a new opportunity to manage devastating cardiovascular disease.

Return to the main page.